Charles River Laboratories International, Inc. and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, entered an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to CDMO capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I trials.   Navega is developing a non-opioid gene therapy treatment for chronic ...